Substance / Medication

Almotriptan

Overview

Active Ingredient
almotriptan
RxNorm CUI
279645

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

4 trials linked to this intervention

4
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine.
Chen Li-Chia, Ashcroft Darren M · Headache · 2007
PMID: 17883521Meta-Analysis
Oral almotriptan in the treatment of migraine: safety and tolerability.
Dodick D W · Headache · 2001
PMID: 11380642Meta-Analysis
Oral sumatriptan and almotriptan--delimiting the MAOI effect.
Oberhardt Florian, Fox Anthony W · Headache · 2012
PMID: 22435741RCT
Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study.
Allais Gianni, Bussone Gennaro, D'Andrea Giovanni et al. · Cephalalgia · 2011
PMID: 20660540ObservationalFull text (PMC)
A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine.
Bartolini Marco, Giamberardino Maria Adele, Lisotto Carlo et al. · J Headache Pain · 2011
PMID: 21437714ObservationalFull text (PMC)
The impact of allodynia on the efficacy of almotriptan when given early in migraine: data from the "Act when mild" study.
Díaz-Insa S, Goadsby P J, Zanchin G et al. · Int J Neurosci · 2011
PMID: 21777163Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Almotriptan (substance)
SNOMED CT
363569003
UMLS CUI
C0914729
RxNorm CUI
279645

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
4
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.